GlassScriptPhysician profile
Lori C Lee
NPI 1346642394
$9,419.69
in general payments reported to CMS, 2019-2025
28 companies · $1,957 in 2025
The $1,957 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,024 · 2022: $1,423 · 2023: $1,934 · 2024: $3,081 · 2025: $1,957.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,883 · Education: $89.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,882.84 |
| Education | $89.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,928.98 | 2021-2025 | |
| Janssen Biotech, INC. | $1,079.39 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $944.88 | 2021-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $697.35 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Phathom Pharmaceuticals, INC. | $571.20 | 2024-2025 | Voquezna |
| Pfizer INC. | $476.76 | 2021-2025 | |
| Celgene Corporation | $465.72 | 2021-2023 | Zeposia |
| Madrigal Pharmaceuticals | $408.77 | 2024-2025 | Rezdiffra, Resmetirom |
| Redhill Biopharma INC. | $400.13 | 2021-2023 | Talicia |
| Janssen Scientific Affairs, LLC | $377.36 | 2024 | Stelara, Remicade, Tremfya |
| Gilead Sciences, INC. | $251.00 | 2021-2025 | Livdelzi |
| E.R. Squibb & Sons, L.L.C. | $233.13 | 2022-2023 | |
| Lilly USA, LLC | $198.46 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $195.10 | 2022-2024 | Ibsrela |
| Aimmune Therapeutics, INC. | $156.48 | 2024-2025 | Vowst |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $149.56 | 2022-2025 | Sucraid |
| Celltrion USA INC. | $140.95 | 2023-2025 | Vegzelma, Yuflyma |
| Genzyme Corporation | $136.54 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $119.74 | 2021-2024 | Dificid |
| Ipsen Biopharmaceuticals, INC | $113.87 | 2024-2025 | Iqirvo, Bylvay |
| Nestle Healthcare Nutrition INC. | $88.33 | 2021-2023 | |
| Ferring Pharmaceuticals INC. | $87.54 | 2021-2023 | Rebyota |
| Intercept Pharmaceuticals, INC. | $58.84 | 2021-2023 | Ocaliva |
| Braintree Laboratories, INC. | $48.39 | 2021-2023 | Sutab |
| Evoke Pharma, INC. | $36.89 | 2023-2024 | Gimoti |
| Novo Nordisk INC | $22.64 | 2024 | |
| Organon LLC | $18.86 | 2022 | |
| Ethicon US, LLC | $12.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.